ORCID iD
Qi. Mahttps://orcid.org/0000-0002-5593-1983 .
Li’an.Huanghttps://orcid.org/0000-0002-0416-7532.
References
1.Norhammar A, Mellbin L and Cosentino F. Diabetes: Prevalence,
prognosis and management of a potent cardiovascular risk factor.Eur J Prev Cardiol 2017; 24: 52-60. DOI:
10.1177/2047487317709554.
2.Chandrasekhar J, Dangas G, Baber U, et al. Impact of insulin treated
and non-insulin-treated diabetes compared to patients without diabetes
on 1-year outcomes following contemporary PCI. Catheter Cardiovasc
Interv 2020 2020/03/13. DOI: 10.1002/ccd.28841.
3.Bawamia BR, Egred M, Jackson M, et al. Percutaneous coronary
intervention for left main stem disease: Impact of diabetes mellitus on
mortality. Catheter Cardiovasc Interv 2020 2020/03/07. DOI:
10.1002/ccd.28818.
4.Shen L, Rorth R, Cosmi D, et al. Insulin treatment and clinical
outcomes in patients with diabetes and heart failure with preserved
ejection fraction. Eur J Heart Fail 2019; 21: 974-984.
2019/07/05. DOI: 10.1002/ejhf.1535.
5.Pepe M, Sardella G, Stefanini GG, et al. Impact of Insulin-Treated and
Noninsulin-Treated Diabetes Mellitus in All-Comer Patients Undergoing
Percutaneous Coronary Interventions With Polymer-Free Biolimus-Eluting
Stent (from the RUDI-FREE Registry). Am J Cardiol 2019; 124:
1518-1527. 2019/09/25. DOI: 10.1016/j.amjcard.2019.08.015.
6.Pi SH, Rhee TM, Lee JM, et al. Outcomes in Patients with Diabetes
Mellitus According to Insulin Treatment After Percutaneous Coronary
Intervention in the Second-Generation Drug-Eluting Stent Era. Am J
Cardiol 2018; 121: 1505-1511. 2018/05/13. DOI:
10.1016/j.amjcard.2018.02.034.
7.Jil M, Rajnikant M, Richard D, et al. The effects of dual-therapy
intensification with insulin or dipeptidylpeptidase-4 inhibitor on
cardiovascular events and all-cause mortality in patients with type 2
diabetes: A retrospective cohort study. Diab Vasc Dis Res 2017;
14: 295-303. 2017/03/24. DOI: 10.1177/1479164116687102.
8.Herman ME, O’Keefe JH, Bell DSH, et al. Insulin Therapy Increases
Cardiovascular Risk in Type 2 Diabetes. Prog Cardiovasc Dis 2017;
60: 422-434. 2017/09/30. DOI: 10.1016/j.pcad.2017.09.001.
9.Anfossi G, Massucco P, Mattiello L, et al. Insulin exerts opposite
effects on platelet function at physiological and supraphysiological
concentrations. Thromb Res 1996; 82: 57-68. 1996/04/01. DOI:
10.1016/0049-3848(96)00051-5.
10.Chakraborty K and Sinha AK. The role of insulin as an antithrombotic
humoral factor. Bioessays 2004; 26: 91-98. 2003/12/30. DOI:
10.1002/bies.10375.
11.Vivas D, Garcia-Rubira JC, Bernardo E, et al. Effects of intensive
glucose control on platelet reactivity in patients with acute coronary
syndromes. Results of the CHIPS Study (”Control de Hiperglucemia y
Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo”).Heart 2011; 97: 803-809. 2011/03/08. DOI:
10.1136/hrt.2010.219949.
12.Vivas D, Garcia-Rubira JC, Bernardo E, et al. Effect of an optimized
treatment with insulin on platelet reactivity after discharge in
patients with an acute coronary syndrome and hyperglycemia. Rev
Esp Cardiol (Engl Ed) 2014; 67: 22-27. 2014/04/30. DOI:
10.1016/j.rec.2013.05.020.
13.Westerbacka J, Yki-Jarvinen H, Turpeinen A, et al. Inhibition of
platelet-collagen interaction: an in vivo action of insulin abolished by
insulin resistance in obesity. Arterioscler Thromb Vasc Biol2002; 22: 167-172. 2002/01/15. DOI: 10.1161/hq0102.101546.
14.Ma Q, Chen GZ, Zhang YH, et al. Clinical outcomes and predictive
model of platelet reactivity to clopidogrel after acute ischemic
vascular events. Chin Med J (Engl) 2019; 132: 1053-1062.
2019/03/22. DOI: 10.1097/CM9.0000000000000210.
15.Tantry US and Gurbel PA. Assessment of oral antithrombotic therapy by
platelet function testing. Nat Rev Cardiol 2011; 8: 572-579. DOI:
10.1038/nrcardio.2011.107.
16.Tang XF, Han YL, Zhang JH, et al. Comparing of light transmittance
aggregometry and modified thrombelastograph in predicting clinical
outcomes in Chinese patients undergoing coronary stenting with
clopidogrel. Chin Med J (Engl) 2015; 128: 774-779. DOI:
10.4103/0366-6999.152611.
17.Gurbel PA, Bliden KP, Navickas IA, et al. Adenosine
diphosphate-induced platelet-fibrin clot strength: a new
thrombelastographic indicator of long-term poststenting ischemic events.Am Heart J 2010; 160: 346-354. DOI: 10.1016/j.ahj.2010.05.034.
18.Shen W, Zhou JY, Gu Y, et al. Establishing a reference range for
thromboelastography maximum amplitude in patients administrating with
antiplatelet drugs. J Clin Lab Anal 2019: e23144. 2019/12/08.
DOI: 10.1002/jcla.23144.
19.Hobson AR, Petley GW, Dawkins KD, et al. A novel fifteen minute test
for assessment of individual time-dependent clotting responses to
aspirin and clopidogrel using modified thrombelastography.Platelets 2007; 18: 497-505. DOI: 10.1080/09537100701329162.
20.Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is
associated with platelet dysfunction in patients with type 2 diabetes
mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol2006; 48: 298-304. DOI: 10.1016/j.jacc.2006.03.038.
21.Alexopoulos D, Vogiatzi C, Stavrou K, et al. Diabetes mellitus and
platelet reactivity in patients under prasugrel or ticagrelor treatment:
an observational study. Cardiovasc Diabetol 2015; 14: 68.
2015/05/31. DOI: 10.1186/s12933-015-0232-1.
22.Yki-Jarvinen H. Nonglycemic effects of insulin. Clin
Cornerstone 2003; Suppl 4: S6-12. 2004/02/28. DOI:
10.1016/s1098-3597(03)90061-5.
23.Spectre G, Ostenson CG, Li N, et al. Postprandial platelet activation
is related to postprandial plasma insulin rather than glucose in
patients with type 2 diabetes. Diabetes 2012; 61: 2380-2384.
2012/06/13. DOI: 10.2337/db11-1806.
24.Spectre G, Stalesen R, Ostenson CG, et al. Meal-induced platelet
activation in diabetes mellitus type 1 or type 2 is related to
postprandial insulin rather than glucose levels. Thromb Res 2016;
141: 93-97. 2016/03/20. DOI: 10.1016/j.thromres.2016.03.009.
25.Trovati M and Anfossi G. Influence of insulin and of insulin
resistance on platelet and vascular smooth muscle cell function. J
Diabetes Complications 2002; 16: 35-40. 2002/03/02.
26.Suslova TE, Sitozhevskii AV, Ogurkova ON, et al. Platelet hemostasis
in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP-
and NO-dependent mechanisms in the insulin-mediated platelet
aggregation. Front Physiol 2014; 5: 501. 2015/01/21. DOI:
10.3389/fphys.2014.00501.
27.Ferreira IA, Eybrechts KL, Mocking AI, et al. IRS-1 mediates
inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein
Gi. J Biol Chem 2004; 279: 3254-3264. 2003/11/07. DOI:
10.1074/jbc.M305474200.
28.Udvardy M, Pfliegler G and Rak K. Platelet insulin receptor
determination in non-insulin dependent diabetes mellitus.Experientia 1985; 41: 422-423. 1985/03/15. DOI:
10.1007/bf02004539.
29.Boden G and Rao AK. Effects of hyperglycemia and hyperinsulinemia on
the tissue factor pathway of blood coagulation. Curr Diab Rep2007; 7: 223-227. 2007/06/06.
30.Gerrits AJ, Koekman CA, van Haeften TW, et al. Platelet tissue factor
synthesis in type 2 diabetic patients is resistant to inhibition by
insulin. Diabetes 2010; 59: 1487-1495. DOI: 10.2337/db09-1008.
31.Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by
insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb
Vasc Biol 2006; 26: 417-422. DOI: 10.1161/01.ATV.0000199519.37089.a0.